Your browser doesn't support javascript.
loading
Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models.
Kamoun, Walid S; Kirpotin, Dmitri B; Huang, Zhaohua Richard; Tipparaju, Suresh K; Noble, Charles O; Hayes, Mark E; Luus, Lia; Koshkaryev, Alexander; Kim, Jaeyeon; Olivier, Ken; Kornaga, Tad; Oyama, Shinji; Askoxylakis, Vasileios; Pien, Christine; Kuesters, Geoffrey; Dumont, Nancy; Lugovskoy, Alexey A; Schihl, Sarah A; Wilton, John H; Geddie, Melissa L; Suchy, James; Grabow, Stephanie; Kohli, Neeraj; Reynolds, C Patrick; Blaydes, Rachel; Zhou, Yu; Sawyer, Andrew J; Marks, James D; Drummond, Daryl C.
Afiliação
  • Kamoun WS; Merrimack Pharmaceuticals, Cambridge, MA, USA.
  • Kirpotin DB; Merrimack Pharmaceuticals, Cambridge, MA, USA.
  • Huang ZR; Merrimack Pharmaceuticals, Cambridge, MA, USA.
  • Tipparaju SK; Merrimack Pharmaceuticals, Cambridge, MA, USA.
  • Noble CO; Merrimack Pharmaceuticals, Cambridge, MA, USA.
  • Hayes ME; ZoneOne Pharma, San Francisco, CA, USA.
  • Luus L; Merrimack Pharmaceuticals, Cambridge, MA, USA.
  • Koshkaryev A; ZoneOne Pharma, San Francisco, CA, USA.
  • Kim J; Merrimack Pharmaceuticals, Cambridge, MA, USA.
  • Olivier K; Merrimack Pharmaceuticals, Cambridge, MA, USA.
  • Kornaga T; Merrimack Pharmaceuticals, Cambridge, MA, USA.
  • Oyama S; Merrimack Pharmaceuticals, Cambridge, MA, USA.
  • Askoxylakis V; Merrimack Pharmaceuticals, Cambridge, MA, USA.
  • Pien C; Merrimack Pharmaceuticals, Cambridge, MA, USA.
  • Kuesters G; Merrimack Pharmaceuticals, Cambridge, MA, USA.
  • Dumont N; Merrimack Pharmaceuticals, Cambridge, MA, USA.
  • Lugovskoy AA; Merrimack Pharmaceuticals, Cambridge, MA, USA.
  • Schihl SA; Merrimack Pharmaceuticals, Cambridge, MA, USA.
  • Wilton JH; Merrimack Pharmaceuticals, Cambridge, MA, USA.
  • Geddie ML; Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
  • Suchy J; Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
  • Grabow S; Merrimack Pharmaceuticals, Cambridge, MA, USA.
  • Kohli N; Merrimack Pharmaceuticals, Cambridge, MA, USA.
  • Reynolds CP; Merrimack Pharmaceuticals, Cambridge, MA, USA.
  • Blaydes R; Merrimack Pharmaceuticals, Cambridge, MA, USA.
  • Zhou Y; Cancer Center, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
  • Sawyer AJ; Cancer Center, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
  • Marks JD; University of California at San Francisco, San Francisco, CA, USA.
  • Drummond DC; Merrimack Pharmaceuticals, Cambridge, MA, USA.
Nat Biomed Eng ; 3(4): 264-280, 2019 04.
Article em En | MEDLINE | ID: mdl-30952988
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptor EphA2 / Nanopartículas / Antineoplásicos Limite: Animals / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptor EphA2 / Nanopartículas / Antineoplásicos Limite: Animals / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article